Press Detail

PRESS RELEASE

Biotest: Managers of Italian Subsidiary have been charged with illegal price fixing

Dreieich, November 17, 2014. In 2010 the public prosecutor of Naples had initiated investigations against numerous employees of various pharmaceutical companies and institutions and charged them with illegal price fixing. Besides the Director of Administration of the University of Naples and the owner of an Italian pharmaceutical wholesaler now also three managers of Biotest Italia Srl, a 100% subsidiary of Biotest AG, are concerned. Biotest AG is not aware of any of such alleged practices and strongly condemns such methods which are not in line with our Pharma Codex and our compliance rules. According to Biotest Italia Srl the company is closely cooperating with the investigating authorities. Biotest AG has retained an independent audit firm to internally investigate the case.

In some media reports about the case it is claimed that Biotest Italia Srl had sold ineffective drugs or preparations without valid market authorization. Biotest decisively rejects as incorrect both claims. The preparations of Biotest are efficacious, safe and fully licensed by the authorities.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart